US20020155140A1 - Parasiticidal formulations that can be applied dermally - Google Patents
Parasiticidal formulations that can be applied dermally Download PDFInfo
- Publication number
- US20020155140A1 US20020155140A1 US10/094,212 US9421202A US2002155140A1 US 20020155140 A1 US20020155140 A1 US 20020155140A1 US 9421202 A US9421202 A US 9421202A US 2002155140 A1 US2002155140 A1 US 2002155140A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- cyclopropyl
- concentration
- spp
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *N(*)/C(C)=*/C Chemical compound *N(*)/C(C)=*/C 0.000 description 7
- BAYGVMXZJBFEMB-UHFFFAOYSA-N OC1=CC=C(C(F)(F)F)C=C1 Chemical compound OC1=CC=C(C(F)(F)F)C=C1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N C=C(C)C Chemical compound C=C(C)C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- ZYYIMVJZNBQYHK-HYWKXYLXSA-N CCN(CC1=CC=C(Cl)N=C1)/C(=N/[N+](=O)[O-])NC.CN(CC1=CC=C(Cl)N=C1)/C(N)=N/[N+](=O)[O-].CN1CN(C)/C(=N\[N+](=O)[O-])N(CC2=CN=C(Cl)S2)C1.N#C/N=C1\CCCN1CC1=CC=C(Cl)N=C1.N#C/N=C1\NCCN1CC1=CC=C(Cl)N=C1.O=[N+]([O-])/N=C1\NCCN1CC1=CC=C(Cl)N=C1.O=[N+]([O-])/N=C1\SCCN1CC1=CC=C(Cl)N=C1.[H]N1CCC(P(=O)(OCC)SC(C)CC)/C1=N\[N+](=O)[O-] Chemical compound CCN(CC1=CC=C(Cl)N=C1)/C(=N/[N+](=O)[O-])NC.CN(CC1=CC=C(Cl)N=C1)/C(N)=N/[N+](=O)[O-].CN1CN(C)/C(=N\[N+](=O)[O-])N(CC2=CN=C(Cl)S2)C1.N#C/N=C1\CCCN1CC1=CC=C(Cl)N=C1.N#C/N=C1\NCCN1CC1=CC=C(Cl)N=C1.O=[N+]([O-])/N=C1\NCCN1CC1=CC=C(Cl)N=C1.O=[N+]([O-])/N=C1\SCCN1CC1=CC=C(Cl)N=C1.[H]N1CCC(P(=O)(OCC)SC(C)CC)/C1=N\[N+](=O)[O-] ZYYIMVJZNBQYHK-HYWKXYLXSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N OC1=CC=C(Cl)C=C1 Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N51/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds having the sequences of atoms O—N—S, X—O—S, N—N—S, O—N—N or O-halogen, regardless of the number of bonds each atom has and with no atom of these sequences forming part of a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Definitions
- the present invention relates to formulations for the dermal control of parasitic insects on animals by means of agonists or antagonists of the nicotinergic acetylcholine receptors of insects.
- Agonists or antagonists of the nicotinergic acetylcholine receptors of insects are known. They include the nicotinyl insecticides and, very particularly, the chloronicotinyl insecticides.
- PCT application WO 93/24 002 discloses that certain 1-[N-(halo-3-pyridylmethyl)]-N-methylamino-alkylamino-2-nitroethylene derivatives are suitable for systemic use against fleas in domestic animals. According to WO 93/24 002, the nonsystemic—i.e. dermal—mode of application is unsuitable for the control of fleas on domestic animals.
- compositions according to the invention have the following composition:
- agonists or antagonists of the nicotinergic acetylcholine receptors of insects in a concentration of from 1 to 20% by weight based on the overall weight of the formulation;
- auxiliaries from the group thickeners, spreading agents, colorants, antioxidants, propellants, preservatives, adhesives, emulsifiers, in a concentration of from 0.025 up to 10% by weight based on the overall weight of the formulation.
- Agonists or antagonists of the nicotinergic acetylcholine receptors of insects are known, for example, from European Offenlegungsschriften (European Published Applications) Nos. 464 830, 428 941, 425 978, 386 565, 383 091, 375 907, 364 844, 315 826, 259 738, 254 859, 235 725, 212 600, 192 060, 163 855, 154 178, 136 636, 303 570, 302 833, 306 696, 189 972, 455 000, 135 956, 471 372, 302 389; German Offenlegungsschriften (German Published Specifications) Nos.
- R represents, hydrogen, optionally substituted radicals from the group acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl;
- A represents a monofunctional group from the series hydrogen, acyl, alkyl, aryl, or represents a bifunctional group which is linked to the radical Z;
- E represents an electron-withdrawing radical
- Z represents a monofunctional group from the series alkyl, —OR, —S-R,
- R represents hydrogen and represents optionally substituted radicals from the series acyl, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl.
- Acyl radicals which may be mentioned are formyl, alkylcarbonyl, arylcarbonyl, alkylsulphonyl, arylsulphonyl, (alkyl)(aryl)phosphoryl, which may in turn be substituted.
- alkyl there may be mentioned C 1-10 -alkyl, especially C 1-4 -alkyl, specifically methyl, ethyl, i-propyl, sec- or t-butyl, which may in turn be substituted.
- aryl there may be mentioned phenyl, naphthyl, especially phenyl.
- aralkyl there may be mentioned phenylmethyl, phenethyl.
- heteroaryl there may be mentioned heteroaryl having up to 10 ring atoms and N, O, S especially N as heteroatoms.
- heteroarylalkyl there may be mentioned heteroarylmethyl, heteroarylethyl having up to 6 ring atoms and N, O, S, especially N as heteroatoms.
- Substituents which may be listed by way of example and preference are: alkyl having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methyl, ethyl, n- and i-propyl and n-, i- and t-butyl; alkoxy having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methoxy, ethoxy, n- and i-propyloxy and n-, i- and t-butyloxy; alkylthio having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methylthio, ethylthio, n- and i-propylthio and n-, i- and t-butylthio; halogenoalkyl having preferably 1 to 4, in particular 1 or 2 carbon atoms and preferably 1 to 5, in particular 1 to 3 halogen atoms, the halogen atoms being identical or different and being
- A additionally represents a bifunctional group.
- optionally substituted alkylene having 1-4, in particular 1-2 C atoms substituents which may be mentioned being the substituents listed earlier above, and it being possible for the alkylene groups to be interrupted by heteroatoms from the series N, O, S.
- a and Z may, together with the atoms to which they are attached, form a saturated or unsaturated heterocyclic ring.
- the heterocyclic ring can contain a further 1 or 2 identical or different heteroatoms and/or hetero-groups.
- Heteroatoms are preferably oxygen, sulphur or nitrogen
- hetero-groups are preferably N-alkyl, where the alkyl in the N-alkyl group preferably contains 1 to 4, in particular 1 or 2 carbon atoms.
- alkyl there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl.
- the heterocyclic ring contains 5 to 7, preferably 5 or 6 ring members.
- heterocyclic ring examples include pyrrolidine, piperidine, piperazine, hexamethyleneimine, hexahydro-1,3,5-triazine, morpholine, each of which may optionally be substituted preferably by methyl.
- E represents an electron-withdrawing radical, in which context particular mention may be made of NO 2 , CN, halogenoalkylcarbonyl such as 1,5-halogeno-C 1-4 -carbonyl especially COCF 3 .
- Z represents optionally substituted radicals, alkyl, —OR, —SR, —NRR, where R and the substituents preferably have the meaning given above.
- Z can form, apart from the abovementioned ring, and together with the atom to which it is attached and with the radical
- the heterocyclic ring can contain a further 1 or 2 identical or different heteroatoms and/or hetero-groups.
- the heteroatoms are preferably oxygen, sulphur or nitrogen, and the hetero-groups N-alkyl, in which case the alkyl or N-alkyl group preferably contains 1 to 4, in particular 1 or 2 carbon atoms.
- alkyl there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl.
- the heterocyclic ring contains 5 to 7, preferably 5 or 6 ring members.
- heterocyclic ring examples include pyrrolidine, piperidine, piperazine, hexamethyleneimine, morpholine and N-methylpiperazine.
- n 1 or 2
- subst. represents one of the above-listed substituents, especially halogen, very particularly chlorine,
- the formulations according to the invention contain the active substance in concentrations of from 0.1 to 20% by weight preferably from 1 to 12.5% by weight.
- Preparations which are diluted before use contain the active substance in concentrations of from 0.5 to 90% by weight preferably from 1 to 50% by weight.
- Suitable solvents are:
- benzyl alcohol or optionally substituted pyrrolidones such as 2-pyrrolidone, 1-(C 2-20 -alkyl)-2-pyrrolidone, in particular 1-ethylpyrrolidone, 1-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, 1-(s- or t- or n-butyl)pyrrolidone, 1-hexylpyrrolidone, 1-(C 2-10 -alkenyl)-2-pyrrolidone such as 1-vinyl-2-pyrrolidone, 1-(C 3-8 -cycloalkyl)-2-pyrrolidone such as 1-cyclohexylpyrrolidone, 1-(C 1-6 -hydroxyalkyl)-2-pyrrolidone, 1-(C 1-6 -alkoxy-C 1-6 -alkyl)-2-pyrrolidone such as 1-(2-hydroxyethylpyr
- They are present in a concentration of at least 20% by weight, preferably from 40 to 90% by weight, particularly preferably from 50 to 90% by weight.
- Suitable additional solvents or cosolvents are: cyclic carbonates or lactones. As such there may be mentioned: ethylene carbonate, propylene carbonate, ⁇ -butyrolactone.
- They are present in a concentration from 5.0 up to 80% by weight, preferably from 7.5 to 50% by weight, particularly preferably from 10 to 50% by weight.
- Suitable further auxiliaries are: preservatives such as benzyl alcohol (not required if already present as solvent), trichlorobutanol, p-hydroxybenzoic esters, n-butanol.
- Thickeners such as: inorganic thickeners such as bentonites, colloidal silicic acid, aluminium monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols, polyvinylpyrrolidones and copolymers thereof, acrylates and methacrylates.
- inorganic thickeners such as bentonites, colloidal silicic acid, aluminium monostearate
- organic thickeners such as cellulose derivatives, polyvinyl alcohols, polyvinylpyrrolidones and copolymers thereof, acrylates and methacrylates.
- Colorants which may be mentioned are all colorants where use on the animal is permitted, which may be dissolved or suspended.
- Auxiliaries are also spreading oils such as di-2-ethylhexyl adipate, isopropyl myristate, dipropylene glycol pelargonate, cyclic and acyclic silicone oils such as dimeticones and also co- and terpolymers thereof with ethylene oxide, propylene oxide and formalin, fatty acid esters, triglycerides, fatty alcohols.
- spreading oils such as di-2-ethylhexyl adipate, isopropyl myristate, dipropylene glycol pelargonate, cyclic and acyclic silicone oils such as dimeticones and also co- and terpolymers thereof with ethylene oxide, propylene oxide and formalin, fatty acid esters, triglycerides, fatty alcohols.
- Antioxidants are sulphites or metabisulphites such as potassium metabisulphite, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol.
- Light stabilizers are, for example, substances from the class of the benzophenones or Novantisol acid.
- Adhesives are, for example, cellulose derivatives, starch derivatives, polyacrylates, naturally occurring polymers such as alginates, gelatin.
- Auxiliaries are also emulsifiers such as nonionic surfactants, for example polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethylstearate, alkylphenol polyglycol ethers;
- nonionic surfactants for example polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethylstearate, alkylphenol polyglycol ethers;
- ampholytic surfactants such as di-Na N-lauryl- ⁇ -iminodipropionate or lecithin;
- anionic surfactants such as Na-lauryl sulphate, fatty alcohol ether sulphates, mono/dialkyl-polyglycol ether orthophosphoric ester monoethanolamine salt; cationic surfactants such as cetyltrimethylammonium chloride.
- auxiliaries are agents with which the formulations according to the invention can be sprayed or squirted onto the skin.
- These are the conventional propellent gases required for spray cans, such as propane, butane, dimethyl ether, CO 2 or halogenated lower alkanes, or mixtures thereof with one another.
- the formulations according to the invention are suitable for the control of parasitic insects which are encountered in animal keeping and animal breeding in domestic and productive anrimals and in zoo and laboratory animals and animals used for experimentation and in the pursuit of hobbies. In this context they are active against all or individual stages of development of the pests and against resistant and normally sensitive species of the pests.
- the pests include:
- the productive and breeding animals include mammals such as, for example, cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur-bearing animals such as, for example, mink, chinchilla or racoon, birds such as, for example, chickens, geese, turkeys, ducks.
- Laboratory animals and those for experimentation include mice, rats, guinea pigs, golden hamsters, dogs and cats.
- the hobby animals include dogs and cats.
- Administration can be effected both prophylactically and therapeutically.
- the further active substances include insecticides such as phosphorus-containing compounds, i.e. phosphates or phosphonates, natural or synthetic pyrethroides, carbamates, amidines, juvenile hormones and juvenoid synthetic active substances, and chitin synthesis inhibitors such as diaryl ethers and benzoylureas.
- insecticides such as phosphorus-containing compounds, i.e. phosphates or phosphonates, natural or synthetic pyrethroides, carbamates, amidines, juvenile hormones and juvenoid synthetic active substances, and chitin synthesis inhibitors such as diaryl ethers and benzoylureas.
- the phosphates or phosphonates include:
- the carbamates include:
- the synthetic pyrethroides include
- amidines include:
- Cyclic macroliths such as invermectins and abamectins.
- invermectins and abamectins.
- 5-0-dimethyl-22,23-dihydroavermectin-A 1a -22,23-dihydroavermectin B 1a and 22,23-dihydroavermectin B b1 cf. for example WHO.
- the juvenile hormones and juvenile hormone-like substances include, in particular, compounds of the following formulae:
- the substituted diaryl ethers include, in particular R 1 R 3 R 5 R 6 Z H H CH 3 H O H H CH 3 2-Cl O 5-F H CH 3 H O H H CF 3 H O H H C 2 H 5 H O H H H H O H H CH 3 H CH 2 H H CH 3 H C(CH 3 ) 2
- the benzoyl ureas include compounds of the formula R 1 R 2 R 4 H Cl CF 3 Cl Cl CF 3 F F CF 3 H F CF 3 H Cl SCF 3 F F SCF 3 H F SCF 3 H Cl OCF 3 F F OCF 3 H F OCF 3 F F F F F F F F F F
- the triazines include compounds of the formula R 1 R 2 R 3 Cyclopropyl H H Cyclopropyl H CH 3 Cyclopropyl H C 2 H 5 Cyclopropyl H C 3 H 7 -n Cyclopropyl H C 4 H 9 -n Cyclopropyl H C 5 H 11 -n Cyclopropyl H C 6 H 13 -n Cyclopropyl H C 7 H 15 -n Cyclopropyl H C 8 H 17 -n Cyclopropyl H C 12 —H 25 -n Cyclopropyl H CH 2 —C 4 H 9 -n Cyclopropyl H CH 2 CH(CH 3 )C 2 H 5 Cyclopropyl H CH 2 CH ⁇ CH 2 Cyclopropyl Cl C 2 H 5 Cyclopropyl Cl C 6 H 13 -n Cyclopropyl Cl C 8 H 17 -n Cyclopropyl Cl C 12 H 25 -n Cyclopropyl H Cyclopropyl Cyclopropyl H COCH 3 Cyclopropy
- the active substance employed is 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinium (common name imidacloprid).
Abstract
The present invention relates to formulations for the dermal control of parasitic insects on animals, having the following composition
agonists or antagonists of the nicotinergic acetylcholine receptors of insects in a concentration of from 1 to 20% by weight based on the overall weight of the formulation;
solvents from the group benzyl alcohol or optionally substituted pyrrolidones in a concentration of at least 20% by weight based on the overall weight of the formulation;
if desired, further solvents from the group consisting of cyclic carbonates or lactones in a concentration of from 5.0 up to 80% by weight based on the overall weight of the formulation;
if desired, further auxiliaries from the group thickeners, spreading agents, colorants, antioxidants, propellants, preservatives, adhesives, emulsifiers, in a concentration of from 0.025 up to 10% by weight based on the overall weight of the formulation.
Description
- The present invention relates to formulations for the dermal control of parasitic insects on animals by means of agonists or antagonists of the nicotinergic acetylcholine receptors of insects.
- Agonists or antagonists of the nicotinergic acetylcholine receptors of insects are known. They include the nicotinyl insecticides and, very particularly, the chloronicotinyl insecticides.
- PCT application WO 93/24 002 discloses that certain 1-[N-(halo-3-pyridylmethyl)]-N-methylamino-alkylamino-2-nitroethylene derivatives are suitable for systemic use against fleas in domestic animals. According to WO 93/24 002, the nonsystemic—i.e. dermal—mode of application is unsuitable for the control of fleas on domestic animals.
- New formulations for the dermal application of agonists or antagonists of the nicotinergic acetylcholine receptors of insects have now been found which are particularly suitable for dermal control of parasitic insects, such as fleas, lice or flies, on animals.
- The formulations according to the invention have the following composition:
- agonists or antagonists of the nicotinergic acetylcholine receptors of insects in a concentration of from 1 to 20% by weight based on the overall weight of the formulation;
- solvents from the group benzyl alcohol or optionally substituted pyrrolidones in a concentration of at least 20% by weight based on the overall weight of the formulation;
- if desired, further solvents from the group consisting of cyclic carbonates or lactones in a concentration of from 5.0 up to 80% by weight based on the overall weight of the formulation;
- if desired, further auxiliaries from the group thickeners, spreading agents, colorants, antioxidants, propellants, preservatives, adhesives, emulsifiers, in a concentration of from 0.025 up to 10% by weight based on the overall weight of the formulation.
- Agonists or antagonists of the nicotinergic acetylcholine receptors of insects are known, for example, from European Offenlegungsschriften (European Published Applications) Nos. 464 830, 428 941, 425 978, 386 565, 383 091, 375 907, 364 844, 315 826, 259 738, 254 859, 235 725, 212 600, 192 060, 163 855, 154 178, 136 636, 303 570, 302 833, 306 696, 189 972, 455 000, 135 956, 471 372, 302 389; German Offenlegungsschriften (German Published Specifications) Nos. 3 639 877, 3 712 307; Japanese Offenlegungsschriften (Japanese Published Applications) Nos. 03 220 176, 02 207 083, 63 307 857, 63 287 764, 03 246 283, 04 9371, 03 279 359, 03 255 072, U.S. Pat. Nos. 5,034,524, 4,948,798, 4,918,086, 5,039,686, 5,034,404; PCT Applications Nos. WO 91/17 659, 91/4965; French Application No. 2 611 114; Brazilian Application No. 88 03 621.
- Express reference is hereby made to the compounds described in these publications and to their preparation.
-
- in which
- R represents, hydrogen, optionally substituted radicals from the group acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl;
- A represents a monofunctional group from the series hydrogen, acyl, alkyl, aryl, or represents a bifunctional group which is linked to the radical Z;
- E represents an electron-withdrawing radical;
- X represents the radicals —CH= or =N—, it being possible for the radical —CH= instead of a H-atom to be linked to the radical Z;
-
- or represents a bifunctional group which is linked to the radical A or to the radical X.
- Particularly preferred compounds of the formula (a) are those in which the radicals have the following meaning:
- R represents hydrogen and represents optionally substituted radicals from the series acyl, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl.
- Acyl radicals which may be mentioned are formyl, alkylcarbonyl, arylcarbonyl, alkylsulphonyl, arylsulphonyl, (alkyl)(aryl)phosphoryl, which may in turn be substituted.
- As alkyl there may be mentioned C1-10-alkyl, especially C1-4-alkyl, specifically methyl, ethyl, i-propyl, sec- or t-butyl, which may in turn be substituted.
- As aryl there may be mentioned phenyl, naphthyl, especially phenyl.
- As aralkyl there may be mentioned phenylmethyl, phenethyl.
- As heteroaryl there may be mentioned heteroaryl having up to 10 ring atoms and N, O, S especially N as heteroatoms. Specifically there may be mentioned thienyl, furyl, thiazolyl, imidazolyl, pyridyl, benzothiazolyl,
- As heteroarylalkyl there may be mentioned heteroarylmethyl, heteroarylethyl having up to 6 ring atoms and N, O, S, especially N as heteroatoms.
- Substituents which may be listed by way of example and preference are: alkyl having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methyl, ethyl, n- and i-propyl and n-, i- and t-butyl; alkoxy having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methoxy, ethoxy, n- and i-propyloxy and n-, i- and t-butyloxy; alkylthio having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methylthio, ethylthio, n- and i-propylthio and n-, i- and t-butylthio; halogenoalkyl having preferably 1 to 4, in particular 1 or 2 carbon atoms and preferably 1 to 5, in particular 1 to 3 halogen atoms, the halogen atoms being identical or different and being preferably fluorine, chlorine or bromine, especially fluorine, such as trifluoromethyl; hydroxyl; halogen, preferably fluorine, chlorine, bromine and iodine, especially fluorine, chlorine and bromine; cyano; nitro; amino; monoalkyl- and dialkylamino having preferably 1 to 4, in particular 1 or 2 carbon atoms per alkyl group, such as methylamino, methyl-ethyl-amino, n- and i-propylamino and methyl-n-butylamino; carboxyl; carbalkoxy having preferably 2 to 4, in particular 2 or 3 carbon atoms, such as carbomethoxy and carboethoxy; sulpho (—SO3H); alkylsulphonyl having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methylsulphonyl and ethylsulphonyl; arylsulphonyl having preferably 6 or 10 aryl carbon atoms, such as phenylsulphonyl, and also heteroarylamino and heteroarylalkylamino such as chloropyridylamino and chloropyridylmethylamino.
- A particularly preferably represents hydrogen and represents optionally substituted radicals from the series acyl, alkyl, aryl, which preferably have the meanings given for R. A additionally represents a bifunctional group. There may be mentioned optionally substituted alkylene having 1-4, in particular 1-2 C atoms, substituents which may be mentioned being the substituents listed earlier above, and it being possible for the alkylene groups to be interrupted by heteroatoms from the series N, O, S.
- A and Z may, together with the atoms to which they are attached, form a saturated or unsaturated heterocyclic ring. The heterocyclic ring can contain a further 1 or 2 identical or different heteroatoms and/or hetero-groups. Heteroatoms are preferably oxygen, sulphur or nitrogen, and hetero-groups are preferably N-alkyl, where the alkyl in the N-alkyl group preferably contains 1 to 4, in particular 1 or 2 carbon atoms. As alkyl there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6 ring members.
- Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethyleneimine, hexahydro-1,3,5-triazine, morpholine, each of which may optionally be substituted preferably by methyl.
- E represents an electron-withdrawing radical, in which context particular mention may be made of NO2, CN, halogenoalkylcarbonyl such as 1,5-halogeno-C1-4-carbonyl especially COCF3.
- X represents —CH= or —N=
- Z represents optionally substituted radicals, alkyl, —OR, —SR, —NRR, where R and the substituents preferably have the meaning given above.
-
- instead of X, a saturated or unsaturated heterocyclic ring. The heterocyclic ring can contain a further 1 or 2 identical or different heteroatoms and/or hetero-groups. The heteroatoms are preferably oxygen, sulphur or nitrogen, and the hetero-groups N-alkyl, in which case the alkyl or N-alkyl group preferably contains 1 to 4, in particular 1 or 2 carbon atoms. As alkyl there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6 ring members.
- Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethyleneimine, morpholine and N-methylpiperazine.
-
- in which
- n represents 1 or 2,
- subst. represents one of the above-listed substituents, especially halogen, very particularly chlorine,
- A, Z, X and E have the meanings given above,
-
- The formulations according to the invention contain the active substance in concentrations of from 0.1 to 20% by weight preferably from 1 to 12.5% by weight.
- Preparations which are diluted before use contain the active substance in concentrations of from 0.5 to 90% by weight preferably from 1 to 50% by weight.
- In general it has proved to be advantageous to administer quantities of from about 0.5 to about 50 mg, preferably from 1 to 20 mg, of active substance per body weight per day in order to achieve effective results.
- Suitable solvents are:
- benzyl alcohol or optionally substituted pyrrolidones such as 2-pyrrolidone, 1-(C2-20-alkyl)-2-pyrrolidone, in particular 1-ethylpyrrolidone, 1-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, 1-(s- or t- or n-butyl)pyrrolidone, 1-hexylpyrrolidone, 1-(C2-10-alkenyl)-2-pyrrolidone such as 1-vinyl-2-pyrrolidone, 1-(C3-8-cycloalkyl)-2-pyrrolidone such as 1-cyclohexylpyrrolidone, 1-(C1-6-hydroxyalkyl)-2-pyrrolidone, 1-(C1-6-alkoxy-C1-6-alkyl)-2-pyrrolidone such as 1-(2-hydroxyethyl)-pyrrolidone, 1-(3-hydroxypropyl)-pyrrolidone, 1-(2-methoxyethyl)-pyrrolidone, 1-(3-methoxypropyl)-pyrrolidone, and also 1-benzylpyrrolidone. Particular mention may be made of benzyl alcohol or n-dodecyl- or n-octylpyrrolidone. These solvents can be employed either alone or in a mixture with additional solvents (cosolvents).
- They are present in a concentration of at least 20% by weight, preferably from 40 to 90% by weight, particularly preferably from 50 to 90% by weight.
- Suitable additional solvents or cosolvents are: cyclic carbonates or lactones. As such there may be mentioned: ethylene carbonate, propylene carbonate, γ-butyrolactone.
- They are present in a concentration from 5.0 up to 80% by weight, preferably from 7.5 to 50% by weight, particularly preferably from 10 to 50% by weight.
- Suitable further auxiliaries are: preservatives such as benzyl alcohol (not required if already present as solvent), trichlorobutanol, p-hydroxybenzoic esters, n-butanol.
- Thickeners such as: inorganic thickeners such as bentonites, colloidal silicic acid, aluminium monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols, polyvinylpyrrolidones and copolymers thereof, acrylates and methacrylates.
- Colorants which may be mentioned are all colorants where use on the animal is permitted, which may be dissolved or suspended.
- Auxiliaries are also spreading oils such as di-2-ethylhexyl adipate, isopropyl myristate, dipropylene glycol pelargonate, cyclic and acyclic silicone oils such as dimeticones and also co- and terpolymers thereof with ethylene oxide, propylene oxide and formalin, fatty acid esters, triglycerides, fatty alcohols.
- Antioxidants are sulphites or metabisulphites such as potassium metabisulphite, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol.
- Light stabilizers are, for example, substances from the class of the benzophenones or Novantisol acid.
- Adhesives are, for example, cellulose derivatives, starch derivatives, polyacrylates, naturally occurring polymers such as alginates, gelatin.
- Auxiliaries are also emulsifiers such as nonionic surfactants, for example polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethylstearate, alkylphenol polyglycol ethers;
- ampholytic surfactants such as di-Na N-lauryl-β-iminodipropionate or lecithin;
- anionic surfactants, such as Na-lauryl sulphate, fatty alcohol ether sulphates, mono/dialkyl-polyglycol ether orthophosphoric ester monoethanolamine salt; cationic surfactants such as cetyltrimethylammonium chloride.
- Further auxiliaries are agents with which the formulations according to the invention can be sprayed or squirted onto the skin. These are the conventional propellent gases required for spray cans, such as propane, butane, dimethyl ether, CO2 or halogenated lower alkanes, or mixtures thereof with one another.
- While being of low toxicity to warm-blooded species, the formulations according to the invention are suitable for the control of parasitic insects which are encountered in animal keeping and animal breeding in domestic and productive anrimals and in zoo and laboratory animals and animals used for experimentation and in the pursuit of hobbies. In this context they are active against all or individual stages of development of the pests and against resistant and normally sensitive species of the pests.
- The pests include:
- from the order of the Anoplura e.g. Haematopinus spp, Linognathus spp., Solenopotes spp., Pediculus spp., Pthirus spp.;
- from the order of the Mallophaga e.g. Trimenopon spp., Menopon spp., Eomenacanthus spp., Menacanthus spp., Trichodectes spp., Felicola spp., Damalinea spp., Bovicola spp;
- from the order of the Diptera e.g. Chrysops spp., Tabanus spp., Musca spp., Hydrotaea spp., Muscina spp., Haematobosca spp., Haematobia spp., Stomoxys spp., Fannia spp., Glossina spp., Lucilia spp., Calliphora spp., Auchmeromyia spp., Cordylobia spp., Cochliomyia spp., Chrysomyia spp., Sarcophaga spp., Wohlfartia spp., Gasterophilus spp., Oesteromyia spp., Oedemagena spp., Hypodea spp., Oestrus spp., Rhinoestrus spp., Melophagus spp., Hippobosca spp.
- From the order of the Siphonaptera e.g. Ctenocephalides spp., Echidnophaga spp., Ceratophyllus spp.
- Particular mention may be made of the action against Siphonaptera, especially against fleas.
- The productive and breeding animals include mammals such as, for example, cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur-bearing animals such as, for example, mink, chinchilla or racoon, birds such as, for example, chickens, geese, turkeys, ducks.
- Laboratory animals and those for experimentation include mice, rats, guinea pigs, golden hamsters, dogs and cats.
- The hobby animals include dogs and cats.
- Administration can be effected both prophylactically and therapeutically.
- In the shaped articles according to the invention, it is also possible for further active substances to be present. The further active substances include insecticides such as phosphorus-containing compounds, i.e. phosphates or phosphonates, natural or synthetic pyrethroides, carbamates, amidines, juvenile hormones and juvenoid synthetic active substances, and chitin synthesis inhibitors such as diaryl ethers and benzoylureas.
- The phosphates or phosphonates include:
- 0-ethyl-0-(8-quinolyl)phenyl thiophosphate (quintiofos),
- 0,0-diethyl 0-(3-chlorometyl-7-coumarinyl)-thiophosphate (coumaphos),
- 0,0-diethyl 0-phenylglycoxylonitrile oxime thiophosphate (phoxim),
- 0,0-diethyl 0-cyanochlorobenzaldoxime thiophosphate (chlorphoxim),
- 0,0-diethyl 0-(4-bromo-2,5-dichlorophenyl) phosphorothionate (bromophos-ethyl),
- 0,0,0′,0′-tetraethyl S,S′-methylene-di(phosphorodithionate) (ethion),
- 2,3-p-dioxanedithiol S,S-bis(0,0-diethyl phosphorodithionate),
- 2-chloro-1-(2,4-dichlorophenyl)-vinyl diethyl phosphate (chlorfenvinphos),
- 0,0-dimethyl 0-(3-methylmethylthiophenyl) thionophosphate (fenthion).
- The carbamates include:
- 2-isopropoxyphenyl methylcarbamate (propoxur),
- 1-naphthyl N-methylcarbamate (carbaryl).
- The synthetic pyrethroides include
- 3-[2-(4-chlorophenyl)-2-chlorovinyl]-2,2-dimethyl-cyclo-propanecarboxylic acid (α-cyano-4-fluoro-3-phenoxybenzyl ester (flumethrin),
- α-cyano(4-fluoro-3-phenoxy)-benzyl 2,2-dimethyl-3-(2,2-dichlorovinyl)-cyclopropanecarboxylate (cyfluthrin) and its enantiomers and stereomers,
- α-cyano-3-phenoxybenzyl (±)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate (deltamethrin),
- α-cyano-3-phenoxybenzyl 2,2-dimethyl-3-(2,2-dichlorovinyl)-cyclopropanecarboxylate (cypermethrin),
- 3-phenoxybenzyl (±)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate (permethrin),
- α-cyano-3-phenoxy-benzyl α-(p-Cl-phenyl)-isovalerate (fenvalerate),
- 2-cyano-3-phenoxybenzyl 2-(2-chloro-α,α,α-trifluoro-p-toluidino)-3-methylbutyrate (fluvalinate).
- The amidines include:
- 3-methyl-2-[2,4-dimethyl-phenylimino]-thiazoline,
- 2-(4-chloro-2-methylphenylimino)-3-methylthiazolidine,
- 2-(4-chloro-2-methylphenylimino)-3-(isobutyl-1-enyl)-thiazolidine
- 1,5-bis-(2,4dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4diene (amitraz).
- Cyclic macroliths such as invermectins and abamectins. In this context there may be mentioned, for example, 5-0-dimethyl-22,23-dihydroavermectin-A1a-22,23-dihydroavermectin B1a and 22,23-dihydroavermectin Bb1 (cf. for example WHO.
-
-
-
- The triazines include compounds of the formula
R1 R2 R3 Cyclopropyl H H Cyclopropyl H CH3 Cyclopropyl H C2H5 Cyclopropyl H C3H7-n Cyclopropyl H C4H9-n Cyclopropyl H C5H11-n Cyclopropyl H C6H13-n Cyclopropyl H C7H15-n Cyclopropyl H C8H17-n Cyclopropyl H C12—H25-n Cyclopropyl H CH2—C4H9-n Cyclopropyl H CH2CH(CH3)C2H5 Cyclopropyl H CH2CH═CH2 Cyclopropyl Cl C2H5 Cyclopropyl Cl C6H13-n Cyclopropyl Cl C8H17-n Cyclopropyl Cl C12H25-n Cyclopropyl H Cyclopropyl Cyclopropyl H COCH3 Cyclopropyl H COCH3 HCl Cyclopropyl H COC2H5 HCl Cyclopropyl H COC2H5 Cyclopropyl H COC3H7-n Cyclopropyl H COC3H7-i Cyclopropyl H COC4H9-t HCl Cyclopropyl H COC4H9-n Cyclopropyl H COC6H13-n Cyclopropyl H COC11—H23-n Cyclopropyl COCH3 COC2H5 Cyclopropyl COC3H7-n COC6H13-n Cyclopropyl COCH3 COC3H7-n Cyclopropyl COC2H5 COC3H7-n Cyclopropyl H COCyclopropyl Cyclopropyl COCyclopropyl COCyclopropyl Cyclopropyl COCH3 COCH3 Isopropyl H H Isopropyl H COCH3 Isopropyl H COC3H7-n Cyclopropyl H CONHCH3 Cyclopropyl H CONHC3H7-i Cyclopropyl CONHCH3 CONHCH3 Cyclopropyl H SCNHCH3 Cyclopropyl H CONHCH2CH═CH2 Cyclopropyl CONHCH2CH═CH2 CONHCH2CH═CH2 Cyclopropyl CSNHCH3 CSNHCH3 - Particular emphasis should be given to the further active substances having the common names propoxur, cyfluthrin, flumethrin, pyriproxyfen, methoprene, diazinon, amitraz, fenthion and levamisol.
- In the examples which follow, the active substance employed is 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinium (common name imidacloprid).
-
Imidacloprid 10 g Propylene carbonate 45 g Benzyl alcohol 45 g ®Belsil DMC 6031 1 g - (A polysiloxane copolymer from Wacker GmbH, D-81737 Munich)
-
Imidacloprid 10 g n-octyl-2-pyrrolidone 44.5 g γ-butyrolactone 44.5 g ®Belsil L 066 1 g - (A polysiloxane copolymer from Wacker GmbH, D-81737 Munich)
-
Imidacloprid 8.5 g n-dodecyl-pyrrolidone 45.25 g γ-butyrolactone 45.25 g ®Belsil L 066 1 g - (Polysiloxane copolymer as spreading agent)
-
Imidacloprid 10 g Benzyl alcohol 89.9 g ®Belsil DMC 6031 0.1 g - (Polysiloxane copolymer as spreading agent)
-
Imidacloprid 12.5 g Benzyl alcohol 70.0 g propylene carbonate 17.5 g -
Imidacloprid 10.0 g 1-cyclohexylpyrrolidone 80.0 g Propylene carbonate 10.0 g -
Imidacloprid 11.0 g Benzyl alcohol 70.0 g Propylene carbonate 15.0 g Isopropyl myristate 4.0 g -
Imidacloprid 12.5 g Benzyl alcohol 70.0 g Propylene carbonate 17.4 g Butylated hydroxytoluene 0.1 g -
Imidacloprid 10.0 g Benzyl alcohol 70.0 g Propylene carbonate 17.5 g Di-2-ethylhexyl adipate 2.5 g -
Imidacloprid 12.5 g 2-pyrrolidone 70.0 g Propylene carbonate 17.5 g -
Imidacloprid 10.0 g Pyriproxyfen 1.0 g Benzyl alcohol 70.0 g Propylene carbonate 18.9 g Butylated hydroxytoluene 0.1 g -
Imidacloprid 12.5 g Triflumuron 2.5 g Benzyl alcohol 60.0 g Propylene carbonate 27.5 g -
Imidacloprid 10.0 g Flumetrin 2.0 g Benzyl alcohol 60.0 g Propylene carbonate 28.0 g -
Imidacloprid 10.0 g Benzyl alcohol 60.0 g Ethylene carbonate 15.0 g Propylene carbonate 15.0 g - 2 ml of the formulation described in Example 1 was poured onto the back of a dog weighing 20 kg which was infested with fleas. The following results were obtained:
Number of fleas Period of time per dog Day Untreated Treated % Action −1 Infestation with 100 fleas 0 Treatment and counting 30 0 100 5, 8 Infestation with 100 fleas 9 Counting 56 0 100 15 Infestation with 100 fleas 16 Counting 76 0 100 19 Infestation with 100 fleas (untreated animals) 250 fleas (treated animals) 20 Counting 39 0 100 26 Infestation with 100 fleas 27 Counting 43 0 100 - 1 ml of the solution according to Example 4 was placed on the shoulders of a dog weighing 20 kg. The animal was infested with 200 fleas after 2 and after 6 days of treatment. On day 3 and on day 7, respectively, of the treatment, the fleas remaining on the dog were counted. No living fleas were found. The action was 100%.
Claims (2)
1. Compositions for the dermal control of parasitic insects on animals, characterized in that it contains
agonists or antagonists of the nicotinergic acetylcholine receptors of insects in a concentration of from 1 to 20% by weight based on the overall weight of the formulation;
solvents from the group benzyl alcohol or optionally substituted pyrrolidones in a concentration of at least 20% by weight based on the overall weight of the formulation;
if desired, furter solvents from the group consisting of cyclic carbonates or lactones in a concentration of from 5.0 up to 80% by weight based on the overall weight of the formulation;
if desired, further auxiliaries from the group thickeners, spreading agents, colorants, antioxidants, propellants, preservatives, adhesives, emulsifiers, in a concentration of from 0.025 up to 10% by weight based on the overall weight of the formulation.
2. Process for the production of the compositions according to claim 1 , characterized in that the active substance is mixed with the stated solvent(s), and the further auxiliaries are added if desired.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/094,212 US20020155140A1 (en) | 1994-12-09 | 2002-03-08 | Parasiticidal formulations that can be applied dermally |
US11/508,055 US20060281792A1 (en) | 1994-12-09 | 2006-08-21 | Parasiticide formulations suitable for dermal application |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4443888.5 | 1994-12-09 | ||
DE4443888A DE4443888A1 (en) | 1994-12-09 | 1994-12-09 | Dermally administrable formulations of parasiticides |
US08/849,259 US6001858A (en) | 1994-12-09 | 1995-11-27 | Parasiticide formulations suitable for dermal application |
US09/435,271 US6372765B1 (en) | 1994-12-09 | 1999-11-05 | Parasiticidal formulations that can be applied dermally |
US10/094,212 US20020155140A1 (en) | 1994-12-09 | 2002-03-08 | Parasiticidal formulations that can be applied dermally |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/435,271 Division US6372765B1 (en) | 1994-12-09 | 1999-11-05 | Parasiticidal formulations that can be applied dermally |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/508,055 Continuation US20060281792A1 (en) | 1994-12-09 | 2006-08-21 | Parasiticide formulations suitable for dermal application |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020155140A1 true US20020155140A1 (en) | 2002-10-24 |
Family
ID=6535391
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/849,259 Expired - Lifetime US6001858A (en) | 1994-12-09 | 1995-11-27 | Parasiticide formulations suitable for dermal application |
US09/435,271 Expired - Lifetime US6372765B1 (en) | 1994-12-09 | 1999-11-05 | Parasiticidal formulations that can be applied dermally |
US10/094,212 Abandoned US20020155140A1 (en) | 1994-12-09 | 2002-03-08 | Parasiticidal formulations that can be applied dermally |
US11/508,055 Abandoned US20060281792A1 (en) | 1994-12-09 | 2006-08-21 | Parasiticide formulations suitable for dermal application |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/849,259 Expired - Lifetime US6001858A (en) | 1994-12-09 | 1995-11-27 | Parasiticide formulations suitable for dermal application |
US09/435,271 Expired - Lifetime US6372765B1 (en) | 1994-12-09 | 1999-11-05 | Parasiticidal formulations that can be applied dermally |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/508,055 Abandoned US20060281792A1 (en) | 1994-12-09 | 2006-08-21 | Parasiticide formulations suitable for dermal application |
Country Status (25)
Country | Link |
---|---|
US (4) | US6001858A (en) |
EP (1) | EP0796042B1 (en) |
JP (1) | JP3257679B2 (en) |
KR (1) | KR100406821B1 (en) |
CN (1) | CN1089553C (en) |
AR (1) | AR001997A1 (en) |
AT (1) | ATE176383T1 (en) |
AU (1) | AU701461B2 (en) |
BR (1) | BR9509873A (en) |
CA (1) | CA2207212C (en) |
CZ (1) | CZ295080B6 (en) |
DE (2) | DE4443888A1 (en) |
DK (1) | DK0796042T3 (en) |
ES (1) | ES2126958T3 (en) |
FI (1) | FI118075B (en) |
GR (1) | GR3029907T3 (en) |
HU (1) | HU215793B (en) |
MY (1) | MY115385A (en) |
NO (1) | NO320426B1 (en) |
NZ (1) | NZ297416A (en) |
PL (1) | PL184426B1 (en) |
SK (1) | SK282286B6 (en) |
TW (2) | TW520271B (en) |
WO (1) | WO1996017520A1 (en) |
ZA (1) | ZA9510433B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050276842A1 (en) * | 2004-06-07 | 2005-12-15 | Zars, Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US20060281792A1 (en) * | 1994-12-09 | 2006-12-14 | Kirkor Sirinyan | Parasiticide formulations suitable for dermal application |
US20070196458A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Compositions and methods for dermally treating neuropathic pain |
US20070196459A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Compositions and methods for treating dermatitis or psoriasis |
US20100267678A1 (en) * | 2004-06-07 | 2010-10-21 | Zars Pharma, Inc. | Flux-enabling compositions and methods for dermal delivery of drugs |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4417742A1 (en) * | 1994-05-20 | 1995-11-23 | Bayer Ag | Non-systemic control of parasites |
DE19519007A1 (en) | 1995-05-24 | 1996-11-28 | Bayer Ag | Insecticidal agents |
DE19613334A1 (en) * | 1996-04-03 | 1997-10-09 | Bayer Ag | Means for controlling parasitic insects and mites on humans |
WO1997040692A1 (en) * | 1996-04-29 | 1997-11-06 | Novartis Ag | Pesticidal compositions |
DE19638045A1 (en) * | 1996-09-18 | 1998-03-19 | Bayer Ag | Injection formulations of avermectins and milbemycins |
DE19654079A1 (en) | 1996-12-23 | 1998-06-25 | Bayer Ag | Endo-ecto-parasiticidal agents |
FR2761232B1 (en) * | 1997-03-26 | 2000-03-10 | Rhone Merieux | PROCESS AND MEANS FOR ERADICATION OF CHIPS IN PREMISES LIVED BY SMALL MAMMALS |
DE19807630A1 (en) * | 1998-02-23 | 1999-08-26 | Bayer Ag | Water-based composition useful for controlling parasitic insects and mites, especially lice, on humans |
DE19807633A1 (en) * | 1998-02-23 | 1999-08-26 | Bayer Ag | Storage-stable water-based composition for controlling parasitic insects, especially fleas, on animals, e.g. livestock and pets |
JP4538863B2 (en) * | 1998-06-08 | 2010-09-08 | 住友化学株式会社 | How to get rid of parasites |
US6140350A (en) * | 1998-06-08 | 2000-10-31 | Sumitomo Chemical Company, Limited | Method for controlling ectoparasites |
JP4232249B2 (en) | 1998-08-05 | 2009-03-04 | 住友化学株式会社 | Harmful arthropod control composition |
JP4288794B2 (en) * | 1999-10-26 | 2009-07-01 | 住友化学株式会社 | Insecticide and acaricide composition |
DE19954394A1 (en) * | 1999-11-12 | 2001-05-17 | Bayer Ag | Use of polysiloxanes with quaternary amino groups as formulation aids and agents contain the same |
US20020103233A1 (en) * | 2000-11-30 | 2002-08-01 | Arther Robert G. | Compositions for enhanced acaricidal activity |
DE10117676A1 (en) * | 2001-04-09 | 2002-10-10 | Bayer Ag | Pesticidal composition, useful for controlling fleas and ticks on animals, contains permethrin and imidacloprid, in N-methylpyrrolidone |
JP2003095813A (en) * | 2001-09-25 | 2003-04-03 | Sumika Life Tech Co Ltd | Liquid agent for expelling exoparasite of animal |
US6663876B2 (en) * | 2002-04-29 | 2003-12-16 | Piedmont Pharmaceuticals, Llc | Methods and compositions for treating ectoparasite infestation |
US20050245582A1 (en) * | 2002-09-12 | 2005-11-03 | The Hartz Mountain Corporation | High concentration topical insecticides containing pyrethroids |
US6588374B1 (en) * | 2002-09-12 | 2003-07-08 | The Hartz Mountain Corporation | High concentration topical insecticide |
DE10301906A1 (en) * | 2003-01-17 | 2004-07-29 | Bayer Healthcare Ag | Arthropod repellent, especially useful for repelling ticks, fleas, mosquitoes and fleas from humans or animals, contains combination of pyrethroid or pyrethrin and nicotinic agonist |
DE10356820A1 (en) * | 2003-12-05 | 2005-07-07 | Bayer Cropscience Ag | Synergistic insecticidal mixtures |
AU2011244913B2 (en) * | 2004-11-04 | 2014-07-24 | Adama Makhteshim Ltd. | Pesticidal composition |
IL165021A0 (en) * | 2004-11-04 | 2005-12-18 | Makhteshim Chem Works Ltd | Pesticidal composition |
JP2006213616A (en) * | 2005-02-02 | 2006-08-17 | Osaka Seiyaku:Kk | Animal ectoparasite expelling agent |
DE102005008949A1 (en) * | 2005-02-26 | 2006-09-14 | Bayer Cropscience Ag | Agrochemical formulation for improving the effect and plant tolerance of crop protection active ingredients |
ES2590906T3 (en) * | 2006-04-28 | 2016-11-24 | Ceva Animal Health, Llc | Topical high concentration insecticides containing permethrin, dinotefuran and pyriproxyphene insect growth regulator |
AU2012203409B2 (en) * | 2006-04-28 | 2012-09-06 | Ceva Animal Health, Llc | High concentration topical insecticides containing pyrethroids |
AU2008324692A1 (en) * | 2007-11-08 | 2009-05-14 | Ceapro Inc. | Avenanthramide-containing compositions |
EP2391207B1 (en) | 2009-01-29 | 2018-03-28 | Bayer Intellectual Property GmbH | Pesticidal control device with high load of active ingredient |
UA108641C2 (en) | 2010-04-02 | 2015-05-25 | PARASITICID COMPOSITION CONTAINING FOUR ACTIVE AGENTS AND METHOD OF APPLICATION | |
CN102070607A (en) * | 2011-01-25 | 2011-05-25 | 南京农业大学 | Pyridine-n-oxide anabasine compound with insecticidal activity, and application thereof |
JO3626B1 (en) | 2012-02-23 | 2020-08-27 | Merial Inc | Topical compositions comprising fipronil and permethrin and methods of use |
CN102973638B (en) * | 2012-11-22 | 2014-12-10 | 青岛绿曼生物工程有限公司 | Compound diazinon composition for treating sarcoptidosis in domestic rabbits, and preparation method thereof |
US9049860B2 (en) | 2013-04-17 | 2015-06-09 | The Hartz Mountain Corporation | Ectoparasiticidal methods |
CA3074620A1 (en) | 2017-09-06 | 2019-03-14 | Bayer Animal Health Gmbh | Topically administrable formulation for the control and prevention of animal parasites |
WO2020150032A1 (en) | 2019-01-16 | 2020-07-23 | Boehringer Ingelheim Animal Health USA Inc. | Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof |
US20200390688A1 (en) * | 2019-06-14 | 2020-12-17 | Piedmont Animal Health Inc. | Long-acting topical formulation and method of use thereof |
SI3815677T1 (en) | 2019-10-30 | 2023-12-29 | Krka, D.D., Novo Mesto | Stable veterinary composition comprising moxidectin and imidacloprid |
AU2021214719A1 (en) | 2020-01-29 | 2022-08-25 | Bayer Animal Health Gmbh | Pharmaceutical composition for controlling parasites on non-human organisms |
CN114028321A (en) * | 2021-12-13 | 2022-02-11 | 青岛农业大学 | Imidacloprid external preparation and preparation method and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114930A (en) * | 1990-05-14 | 1992-05-19 | Merck & Co., Inc. | Avermectin derivatives with a spacer inserted between the disaccharide and the aglycone useful as antiparasitic agents |
US6255350B1 (en) * | 1997-10-14 | 2001-07-03 | Isp Investments Inc. | Stabilized concentrates of water unstable AZA compounds and o/w miniemulsions thereof |
US6300348B1 (en) * | 1996-04-03 | 2001-10-09 | Bayer Aktiengesellschaft | Pesticide for parasitic insects and acarids on humans |
US6369054B1 (en) * | 1998-02-23 | 2002-04-09 | Bayer Ag | Aqueous agents for combating parasitic insects and acarina in human beings |
US6372765B1 (en) * | 1994-12-09 | 2002-04-16 | Bayer Aktiengesellschaft | Parasiticidal formulations that can be applied dermally |
US20030055089A1 (en) * | 1996-12-23 | 2003-03-20 | Kirkor Sirinyan | Endoparasiticidal and ectoparasiticidal agents |
US20030109496A1 (en) * | 1999-12-16 | 2003-06-12 | Kirkor Sirinyan | Fluid insecticidal formulations for treatment of parasitic insect larvae by dermal application |
US20030162773A1 (en) * | 1998-02-23 | 2003-08-28 | Kirkor Sirinyan | Aqueous formulations of parasiticides for skin applications |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB802111A (en) * | 1956-09-25 | 1958-10-01 | Irwin Irville Lubowe | Improved non-toxic pesticidal compositions |
NL180633C (en) * | 1973-06-22 | 1900-01-01 | Bayer Ag | PROCESS FOR PREPARING AN ANTHELMINTIC EFFECTIVE VETERINARY Pour-on Preparation. |
US4415563A (en) * | 1980-04-04 | 1983-11-15 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclononan-2-ones |
JPS6351326A (en) * | 1986-08-22 | 1988-03-04 | Nisshin Flour Milling Co Ltd | Nicorandil agent for external use |
GB8718899D0 (en) * | 1987-08-10 | 1987-09-16 | Avon Rubber Plc | Bushing for tracked vehicle |
US4804541A (en) * | 1987-08-11 | 1989-02-14 | Moleculon, Inc. | Transdermal administration using benzyl alcohol |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4960771A (en) * | 1988-07-12 | 1990-10-02 | Rajadhyaksha Vithal J | Oxazolidinone penetration enhancing compounds |
DE3825172A1 (en) * | 1988-07-23 | 1990-01-25 | Bayer Ag | MEANS FOR CONTROLLING FLOWS |
EP0388122A1 (en) * | 1989-03-13 | 1990-09-19 | Scientific Chemicals (Proprietary) Limited | Pesticidal formulation |
GB2236250A (en) * | 1989-09-26 | 1991-04-03 | Mentholatum Co Ltd | Ibuprofen solutions and topical compositions |
AU631259B2 (en) * | 1989-12-18 | 1992-11-19 | Ciba-Geigy Ag | Formulations of benzoylphenyl ureas for combating ectoparasites |
JPH04112804A (en) * | 1990-08-31 | 1992-04-14 | Takeda Chem Ind Ltd | Insecticide composition |
JP3086925B2 (en) * | 1990-09-07 | 2000-09-11 | 武田薬品工業株式会社 | Insecticidal composition |
IL99445A (en) * | 1990-09-18 | 1996-06-18 | Ciba Geigy Ag | Picoline oxides process for their preparation and insecticidal and acaricidal compositions containing them |
CA2106483A1 (en) * | 1991-03-19 | 1992-09-20 | Vithal J. Rajadhyaksha | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers |
US5439924A (en) * | 1991-12-23 | 1995-08-08 | Virbac, Inc. | Systemic control of parasites |
AU673329B2 (en) * | 1992-05-23 | 1996-11-07 | Novartis Ag | 1-(N-(halo-3-pyridylmethyl))-N-methylamino-1-alkylamino-2- nitroethylene derivatives for use against fleas on pets |
DE4232561A1 (en) * | 1992-09-29 | 1994-03-31 | Bayer Ag | Fighting fish parasites |
DE4417742A1 (en) * | 1994-05-20 | 1995-11-23 | Bayer Ag | Non-systemic control of parasites |
DE4419814A1 (en) * | 1994-06-07 | 1995-12-14 | Bayer Ag | Endoparasiticides |
-
1994
- 1994-12-09 DE DE4443888A patent/DE4443888A1/en not_active Withdrawn
-
1995
- 1995-11-15 TW TW087120690A patent/TW520271B/en not_active IP Right Cessation
- 1995-11-15 TW TW084112054A patent/TW360494B/en not_active IP Right Cessation
- 1995-11-17 AR ARP950100220A patent/AR001997A1/en unknown
- 1995-11-27 EP EP95941028A patent/EP0796042B1/en not_active Expired - Lifetime
- 1995-11-27 US US08/849,259 patent/US6001858A/en not_active Expired - Lifetime
- 1995-11-27 KR KR1019970703787A patent/KR100406821B1/en not_active IP Right Cessation
- 1995-11-27 NZ NZ297416A patent/NZ297416A/en not_active IP Right Cessation
- 1995-11-27 AT AT95941028T patent/ATE176383T1/en active
- 1995-11-27 PL PL95320674A patent/PL184426B1/en unknown
- 1995-11-27 SK SK717-97A patent/SK282286B6/en not_active IP Right Cessation
- 1995-11-27 BR BR9509873A patent/BR9509873A/en not_active IP Right Cessation
- 1995-11-27 CN CN95197553A patent/CN1089553C/en not_active Expired - Lifetime
- 1995-11-27 AU AU42569/96A patent/AU701461B2/en not_active Expired
- 1995-11-27 WO PCT/EP1995/004667 patent/WO1996017520A1/en active IP Right Grant
- 1995-11-27 DE DE59505055T patent/DE59505055D1/en not_active Expired - Lifetime
- 1995-11-27 ES ES95941028T patent/ES2126958T3/en not_active Expired - Lifetime
- 1995-11-27 CA CA2207212A patent/CA2207212C/en not_active Expired - Lifetime
- 1995-11-27 DK DK95941028T patent/DK0796042T3/en active
- 1995-11-27 JP JP51729596A patent/JP3257679B2/en not_active Expired - Lifetime
- 1995-11-27 CZ CZ19971727A patent/CZ295080B6/en not_active IP Right Cessation
- 1995-11-27 HU HU9701901A patent/HU215793B/en unknown
- 1995-12-06 MY MYPI95003760A patent/MY115385A/en unknown
- 1995-12-08 ZA ZA9510433A patent/ZA9510433B/en unknown
-
1997
- 1997-06-05 FI FI972387A patent/FI118075B/en not_active IP Right Cessation
- 1997-06-06 NO NO19972592A patent/NO320426B1/en not_active IP Right Cessation
-
1999
- 1999-04-07 GR GR990400998T patent/GR3029907T3/en unknown
- 1999-11-05 US US09/435,271 patent/US6372765B1/en not_active Expired - Lifetime
-
2002
- 2002-03-08 US US10/094,212 patent/US20020155140A1/en not_active Abandoned
-
2006
- 2006-08-21 US US11/508,055 patent/US20060281792A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114930A (en) * | 1990-05-14 | 1992-05-19 | Merck & Co., Inc. | Avermectin derivatives with a spacer inserted between the disaccharide and the aglycone useful as antiparasitic agents |
US6372765B1 (en) * | 1994-12-09 | 2002-04-16 | Bayer Aktiengesellschaft | Parasiticidal formulations that can be applied dermally |
US6300348B1 (en) * | 1996-04-03 | 2001-10-09 | Bayer Aktiengesellschaft | Pesticide for parasitic insects and acarids on humans |
US20030055089A1 (en) * | 1996-12-23 | 2003-03-20 | Kirkor Sirinyan | Endoparasiticidal and ectoparasiticidal agents |
US20040014689A1 (en) * | 1996-12-23 | 2004-01-22 | Kirkor Sirinyan | Endoparaciticidal and ectoparasiticidal agents |
US6255350B1 (en) * | 1997-10-14 | 2001-07-03 | Isp Investments Inc. | Stabilized concentrates of water unstable AZA compounds and o/w miniemulsions thereof |
US6369054B1 (en) * | 1998-02-23 | 2002-04-09 | Bayer Ag | Aqueous agents for combating parasitic insects and acarina in human beings |
US20030162773A1 (en) * | 1998-02-23 | 2003-08-28 | Kirkor Sirinyan | Aqueous formulations of parasiticides for skin applications |
US20030109496A1 (en) * | 1999-12-16 | 2003-06-12 | Kirkor Sirinyan | Fluid insecticidal formulations for treatment of parasitic insect larvae by dermal application |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281792A1 (en) * | 1994-12-09 | 2006-12-14 | Kirkor Sirinyan | Parasiticide formulations suitable for dermal application |
US20050276842A1 (en) * | 2004-06-07 | 2005-12-15 | Zars, Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US20070196458A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Compositions and methods for dermally treating neuropathic pain |
US20070196459A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Compositions and methods for treating dermatitis or psoriasis |
US20100267678A1 (en) * | 2004-06-07 | 2010-10-21 | Zars Pharma, Inc. | Flux-enabling compositions and methods for dermal delivery of drugs |
US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
US8741332B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US9675562B2 (en) | 2004-06-07 | 2017-06-13 | Crescita Therapeutics Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6372765B1 (en) | Parasiticidal formulations that can be applied dermally | |
US7384938B2 (en) | Aqueous formulations of parasiticides for skin applications | |
US6300348B1 (en) | Pesticide for parasitic insects and acarids on humans | |
MXPA97004222A (en) | Formulations of administrative parasiticides porvia derm | |
MXPA00008051A (en) | Aqueous formulations of parasiticides for skin application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |